Table 2.
Pooled, and stratified by received respiratory support 6-month outcomes.
| Pooled | Stratified | OR (95% CI), p-value | aOR# (95% CI), p-value | ||
|---|---|---|---|---|---|
| N (%) | No supplemental oxygen or low-flow oxygen, n (%) | HFNC or NIV or IMV, n (%) | |||
| 355 | 287 | 68 | |||
| Outcomes | |||||
| Symptoms | 108/355 (30.3) | 68 (23.8) | 40 (57.1) | 4.27 (2.48–7.38), < 0.01 | 4.00 (1.99–8.05), < 0.01 |
| Dyspnea | 64/355 (18.0) | 39 (13.7) | 25 (35.7) | 3.50 (1.93–6.35), < 0.01 | 2.80 (1.28–6.16), 0.01 |
| mMRC scale 0 | 292 (82.0) | 247 (86.4) | 45 (64.3) | *3.52 (1.94–6.37), < 0.01 | *2.85 (1.30–6.25), < 0.01 |
| mMRC scale 1 | 52 (14.6) | 33 (11.5) | 19 (27.1) | ||
| mMRC scale 2 | 8 (2.3) | 5 (1.8) | 3 (4.3) | ||
| mMRC scale 3 | 3 (0.8) | 1 (1.3) | 2 (2.9) | ||
| mMRC scale 4 | 1 (0.3) | 0 (0.0) | 1 (1.4) | ||
| Neurological symptoms | 22/355 6.2) | 6 (2.1) | 16 (22.9) | 13.78 (5.16–36.80), < 0.01 | 9.72 (2.78–34.00), < 0.01 |
| COVID-related re-hospitalization | 10/384 (2.6) | 8/308 (2.6) | 2/76 (2.6) | 1.01 (0.21–4.87), 0.99 | 2.67 (0.34–20.87), 0.35 |
| Overall 6-month mortality | 87/471 (18.5) | 73 (19.2) | 14 (15.6) | 0.78 (0.42–1.45), 0.43 | 0.53 (0.23–1.19), 0.12 |
| IgG | 177/190 (93.2) | 121/131 (92.4) | 56/59 (94.9) | 1.54 (0.41–5.82), 0.52 | 1.27 (0.21–7.57), 0.79 |
| Walking test 0 | 92/104 (87.6) | 45 (91.8) | 47 (84.0) | *2.15 (0.62–7.49), 0.23 | *2.68 (0.48–15.03), 0.26 |
| Walking test 1 | 12/104 (11.4) | 4 (8.2) | 8 (14.2) | ||
| Walking test 2 | 1/104 (1.0) | 0 (0.0) | 1 (1.8) | ||
| Parenchymal CT 0, 1, 2 (normal or mild damage) | 102/105 (98.1) | 42 (97.7) | 60 (96.8) | 1.43 (0.13–16.32), 0.77 | 4.29 (0.15–123.07), 0.40 |
| Parenchymal CT 3, 4 (moderate to severe damage) | 3/105 (2.9) | 1 (2.3) | 2 (3.2) | ||
| Interstitial CT 0, 1, 2 (normal or mild damage) | 53/105 (50.5) | 31 (70.5) | 22 (37.1) | 4.04 (1.77–9.25), < 0.01 | 2.73 (0.90–8.28), 0.08 |
| Interstitial CT 3, 4 (moderate to severe damage) | 52/105 (49.5) | 13 (29.5) | 39 (62.9) | ||
CT computed tomography, HFNC high-flow nasal cannula, IgG immunoglobulin G, IMV invasive mechanical ventilation, mMRC Modified Medical Research Council, NIV non-invasive mechanical ventilation, TC computed tomography.
*For every 1 point increase.
#Adjusted for gender, age, obesity, and NEWS2 (National Early Warning Score 2) at admission.